Walter Investment Management Corp (WAC) Jumps 5.65% on January 05

Equities Staff  |

Walter Investment Management Corp (WAC) was among the biggest gainers on the Russell 2000 for Tuesday January 05 as the stock popped 5.65% to $15.14, representing a gain of $0.81 per share. Some 176,253 shares traded hands on 1,346 trades, compared with an average daily volume of 257,313 shares out of a total float of 37.8 million. The stock opened at $14.33 and traded with an intraday range of $15.17 to $14.26.

After today's gains, Walter Investment Management Corp reached a market cap of $572.33 million. Walter Investment Management Corp has had a trading range between $24.35 and $9.63 over the last year, and it had a 50-day SMA of $12.96 and a 200-day SMA of $16.89.

Walter Investment Management Corp is a diversified mortgage banking firm. It provides servicing and origination of residential loans, including reverse loans.

Walter Investment Management Corp is based out of Tampa, FL and has some 5,900 employees. Its CEO is Denmar J. Dixon.

For a complete fundamental analysis analysis of Walter Investment Management Corp, check out’s Stock Valuation Analysis report for WAC. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.